“…Problems involved are lack of standardized procedures, lack of reliable quality control materials, changing immunoreactivity due to self-association and aggregation of the particles, varying content of lipid which may mask epitopes, and different affinities of the antisera. Assays and assay modifications have been recently described for apoA-I (350)(351)(352)(353)(354), apoB (352,353,(355)(356)(357)(358), Lp(a) (359), apoC (353), apoC-III (360,361). Reference ranges are not yet well defined, especially those of apolipoproteins (362,363).…”